How Dogs Influence Our Microbiome and Well-Being
Fetch! Dogs may make us happy in more ways than one
Monica Click/Shutterstock
Dogs have long been known as man’s best friend, but recent research suggests that their influence on our well-being goes beyond companionship. A study involving mice indicates that owning a dog can lead to changes in our microbiome, specifically promoting empathetic and social behaviors.
Studies have shown that pets, including dogs, can improve our life satisfaction and impact our gut microbiome. The microbiome, in turn, has been linked to mental health and personality traits. Researchers, led by Takefumi Kikusui at Azabu University in Japan, set out to investigate how owning a dog affects our microbiome and overall well-being.
The study involved surveys from caregivers of 343 adolescents in Tokyo, aged 12 to 14, where social behaviors were reported. Results showed that adolescents with pet dogs exhibited less social withdrawal and aggression compared to non-dog owners. Saliva samples also revealed a higher abundance of certain bacterial species, such as Streptococcus, in adolescents with dogs, which has been associated with reduced depressive symptoms.
According to Gerard Clarke from University College Cork in Dublin, Ireland, interacting closely with dogs exposes us to their microbes, which can travel to our gastrointestinal tract and produce anti-inflammatory chemicals like short-chain fatty acids, beneficial for mental health.
In a groundbreaking part of the study, oral microbes from dog owners and non-dog owners were transplanted into germ-free mice. Behavioral tests showed that mice receiving transplants from dog owners displayed more empathetic and social behaviors, indicating a potential link between owning a dog, microbiome composition, and behavior.
Further research is needed to explore the geographical variations in microbial exposures and their impact on well-being. Understanding these microbial changes could lead to the development of probiotics that mimic the effects of owning a dog, benefiting individuals without pets.
As the world continues to grapple with the ongoing COVID-19 pandemic, scientists and researchers are racing against time to develop effective treatments and vaccines to combat the virus. One promising avenue of research involves the use of monoclonal antibodies, which have shown great potential in treating and preventing COVID-19.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens, such as viruses. These antibodies are designed to target specific proteins on the surface of the virus, blocking its ability to infect human cells and replicate. By targeting these critical proteins, monoclonal antibodies can effectively neutralize the virus and prevent it from causing further harm.
Several pharmaceutical companies and research institutions have been working tirelessly to develop monoclonal antibodies for COVID-19. One of the most promising treatments currently in development is a cocktail of monoclonal antibodies developed by Regeneron Pharmaceuticals. In clinical trials, this antibody cocktail has shown to significantly reduce viral load and improve symptoms in patients with mild to moderate COVID-19.
Another promising monoclonal antibody treatment is being developed by Eli Lilly and Company. This treatment, known as bamlanivimab, has received emergency use authorization from the Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients. Clinical trials have shown that bamlanivimab can reduce hospitalizations and emergency room visits in patients with COVID-19.
In addition to treating COVID-19, monoclonal antibodies are also being explored as a potential preventive measure. Researchers are investigating whether monoclonal antibodies can be used to provide temporary immunity to the virus, similar to a vaccine. This approach, known as passive immunization, could help protect individuals who are at high risk of exposure to COVID-19, such as healthcare workers and elderly individuals.
Despite the promising results seen in clinical trials, challenges remain in the widespread adoption of monoclonal antibodies for COVID-19. These treatments are expensive to produce and administer, and there are concerns about their long-term efficacy and potential side effects. Additionally, there is a limited supply of monoclonal antibodies, which could hinder their availability to those who need them most.
As researchers continue to study and refine monoclonal antibody treatments for COVID-19, it is clear that these therapies have the potential to play a crucial role in the fight against the virus. By targeting the virus at the molecular level, monoclonal antibodies offer a promising new approach to treating and preventing COVID-19, providing hope for a brighter future in the midst of a global health crisis.
